Raymond Tubbs

BASIC SCIENCE REVIEW

A. Carbone, A. Gloghini, K. Devaney, 2008 .

Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.

T. Olencki, J. Finke, P. Rayman, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

G. T. Budd, J. Finke, P. Rayman, 1991, Cancer research.

Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma

J. Finke, M. Caulfield, C. Campbell, 1998, International journal of cancer.

Lymphoma of the parotid gland

D. Kraus, H. Tucker, B. Wood, 1993, The Laryngoscope.

Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen

R. Tubbs, S. Deodhar, R. Bukowski, 1985, Cancer.

Phase 1 Trial of Subcutaneous IL-6 in Patients With Refractory Cancer: Clinical and Biologic Effects

G. T. Budd, T. Olencki, J. Finke, 2000, Journal of immunotherapy.

Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.

T. Olencki, A. Novick, J. Finke, 1997, Journal of immunotherapy.